The Viral Keratitis drugs in development market research report provides comprehensive information on the therapeutics under development for Viral Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Viral Keratitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Viral Keratitis and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Viral Keratitis by 11 companies/universities/institutes. The top development phase for Viral Keratitis is preclinical with nine drugs in that stage. The Viral Keratitis pipeline has 14 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Viral Keratitis pipeline products market are: Shulov Innovative Science, Zhejiang Raytone Biotechnology and Fox Chase Chemical Diversity Center.
The key targets in the Viral Keratitis pipeline products market include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16), Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM), and Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1).
The key mechanisms of action in the Viral Keratitis pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with one drug in Phase II. The Viral Keratitis pipeline products include eight routes of administration with the top ROA being Ophthalmic and five key molecule types in the Viral Keratitis pipeline products market including Small Molecule, and Synthetic Peptide.
Viral Keratitis overview
Viral infection of the cornea is often caused by the herpes simplex virus (HSV) which frequently leaves what is called a ‘dendritic ulcer’. Keratitis is a condition in which the eye’s cornea, the clear dome on the front surface of the eye, becomes inflamed. The condition is often marked by moderate to intense pain and usually involves any of the following symptoms: pain, impaired eyesight, photophobia (light sensitivity), red eye and a ‘gritty’ sensation.
For a complete picture of Viral Keratitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
